Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District ...

Cassava Sciences shares dropped after the company agreed to a $40 million settlement with the Securities and Exchange ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...

Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience ...

Cassava Sciences shares fell in premarket trading Friday after regulators said the company, along with two former executives, will pay more than $40 million to settle charges related to misleading ...

Cassava Sciences settles SEC charges for $40M over misleading Alzheimer's drug trial results, ex-CEO and SVP also face negligence charges.

These are the most popular stories from the Wall Street Journal. These stories have not been verified and we cannot vouch their accuracy. U.S.

Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...

The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug ...

Relatedly, the SEC also charged Hoau-Yan Wang, a Cassava consultant and an associate professor at the City University of New York's Medical School, for manipulating the reported clinical trial results ...

After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue ...